Drugs / BSG-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03736122 | Jan 2019 → Jan 2022 | peritoneal neoplasm, pleural neoplasm | BioSyngen Pte Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BSG-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03736122 ↗ |
| Route | Inhaled | “with Inhalation as route of administration using nebulizer.” NCT03736122 ↗ |